Our Approach

Collaboration propels innovation

At IGI, we believe in the power of collaboration to drive innovation.

Collaboration that helps us combine forces of expertise, technology, speed and reach.
Collaboration that helps us transform the world of oncology by creating novel cutting-edge therapeutics, faster.
Collaboration that kindles new hope for oncology patients, their families and healthcare professionals.

Our identity is a crisp and apt expression on our belief.

The letters IGI combine with a graphic of a compass to suggest how collaboration guides IGI towards innovation.

Our brand line ‘Collaboration propels innovation’ completes the message.

Approach

Our vision

Daring to imagine a world where cure is possible. Moving beyond hope, with therapies that will forever transform medicine and lives.

Approach

Our mission

To co-create innovative treatment solutions that make healthier living possible.

Cancer cure through collaboration

At IGI, we strive to fast-track the development of new cancer cures through collaboration. We focus on creating cutting-edge solutions to treat hematological malignancies and solid tumors through collaborations with other institutions including but not limited to other biotech companies, start-ups, investors and academia. We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform, and ISB 2001 (CD 38 x BCMA x CD3 trispecific antibody) is in development for patients with multiple myeloma.

Strategic priorities for biologics discovery research in oncology

Focus on disease-centric approach and leverage BEAT® antibody engineering platform to deliver first-in-class candidates.


Multiple Myeloma (MM):


Deliver a competitive MM portfolio by advancing next wave of T-cell engagers and innate immune engagers (e.g., NK, macrophages)


Solid Tumors:


Accelerate delivery of innovative concepts by leveraging tri-specific T-cell and innate immune engagers (e.g., NK, macrophages)
Leverage BEAT® in solid tumors


Multiple Myeloma (MM):

Deliver a competitive MM portfolio by advancing next wave of T-cell engagers and innate immune engagers (e.g., NK, macrophages)

Solid Tumors:

Accelerate delivery of innovative concepts by leveraging tri-specific T-cell and innate immune engagers (e.g., NK, macrophages)

Leverage BEAT® in solid tumors